Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats

Area of Science:

• Bone Biology
• Pharmacology
• Osteoporosis Research

Background:

• Menatetrenone (MK-4) is known to inhibit bone resorption and enhance osteoblast mineralization.
• Osteopenia, characterized by bone volume loss, affects bone health and microstructure.
• Sciatic neurectomy in rats is a model used to study osteopenia and its effects on bone.

Purpose of the Study:

• To investigate the beneficial effects of MK-4 on osteoblast dysfunction in an osteopenia rat model.
• To evaluate MK-4's impact on trabecular microstructure and bone volume loss.
• To determine if MK-4 can prevent or mitigate bone loss induced by sciatic neurectomy.

Main Methods:

• Male Sprague-Dawley rats underwent sciatic neurectomy and daily MK-4 supplementation.
• Bone mineral density (BMD) and microstructural parameters were assessed.
• Osteoclast surface (Oc.S/BS), osteoclast number (N.Oc/B.Pm), and mineral apposition rate (MAR) were measured.

Main Results:

• MK-4 administration prevented a decrease in femur distal metaphyseal bone mineral density.
• Low-dose MK-4 increased mineral apposition rate (MAR) and bone formation rate (BFR).
• MK-4 maintained normal levels of osteoclast surface (Oc.S/BS) and osteoclast number (N.Oc/B.Pm), suggesting preserved bone turnover.

Conclusions:

• MK-4 effectively reduces trabecular bone loss in a rat model of osteopenia.
• Menatetrenone (MK-4) partially prevents osteoblast dysfunction.
• MK-4 contributes to preserving trabecular microstructure and bone health during osteopenia.